Navigation Links
AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
Date:5/16/2013

REDWOOD CITY, Calif., May 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King , President and CEO, will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York, NY.  The presentation is scheduled for Wednesday, May 22, 2013 at 9:30 a.m. ET/6:30 a.m. PT.

The presentation will be webcast live and can be accessed through the Investors page followed by referring to the Event Calendar page at www.acelrx.com.  For those not available to listen to the live broadcast, a replay of the presentation will be archived and available through www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, or NanoTab System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced results from two Phase 3 clinical trials for the NanoTab System, and a third Phase 3 study has completed enrollment, with data expected in the second quarter of 2013.  A New Drug Application submission is planned for the third quarter of 2013. AcelRx recently announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the release and anticipated timing of additional NanoTab System clinical trial data, anticipated timing of completion of AcelRx Pharmaceuticals' current clinical trials, submission of the NDA, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2013.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo:  http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
2. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
3. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
4. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
5. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
6. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
7. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
8. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. AcelRx Pharmaceuticals Provides Clinical Trial Updates
10. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
11. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the ... are around 150 million people worldwide that are affected by treatment-resistant hypertension, resulting ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... since 2005, announced it has successfully completed enrollment of 690 patients for a ... a dose ranging, multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial ...
(Date:8/14/2019)... ... August 14, 2019 , ... Bach Pharma, Inc., a ... its drug platform GVT (Monosodium Luminol), created to treat and cure multiple neurodegenerative ... data from multiple animal studies have proven that GVT has the potential to ...
Breaking Medicine Technology:
(Date:8/14/2019)... , ... August 14, 2019 , ... Teguar Corporation has ... in America. This list has long-been established as a mark of success for some ... Dell, and Oracle. Teguar made the list in 2015, 2016 and 2017. This year, ...
(Date:8/14/2019)... ... August 14, 2019 , ... ... Team Assistant support, has earned a place on the Inc. magazine 500/5000 list ... inclusion marks nearly a decade of ScribeAmerica’s recognition as one of the fastest ...
(Date:8/14/2019)... ... August 13, 2019 , ... New Hampshire-based Vera Roasting Company , makers ... expansion of its line of CBD-infused coffees with the release of a new higher-dosage ... bag. , “We are excited to expand our CBD-infused product lines to include ...
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... In a ... the purpose of doubt in your belief systems. , “Doubt can obliterate your old ... on the path to examining them to expand your understanding and your awareness. Trust ...
(Date:8/14/2019)... ... August 14, 2019 , ... While it is commonly ... their food and beverage choices can help them manage and, in some cases, reverse ... finds that about a quarter of U.S. adults are trying to manage a health ...
Breaking Medicine News(10 mins):